Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells

SIMPLE SUMMARY: By combining drug screens, transcriptomic studies, and in vitro assays, our study identified the natural product toyocamycin as a potent and selective CDK9 inhibitor. Thus, toyocamycin can be used as a new small molecule to modulate CDK9 activity in preclinical research. Through dock...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandey, Somnath, Djibo, Rahinatou, Darracq, Anaïs, Calendo, Gennaro, Zhang, Hanghang, Henry, Ryan A., Andrews, Andrew J., Baylin, Stephen B., Madzo, Jozef, Najmanovich, Rafael, Issa, Jean-Pierre J., Raynal, Noël J.-M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324262/
https://www.ncbi.nlm.nih.gov/pubmed/35884401
http://dx.doi.org/10.3390/cancers14143340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324262/
https://www.ncbi.nlm.nih.gov/pubmed/35884401
http://dx.doi.org/10.3390/cancers14143340

Ejemplares similares